It will be informative to determine the feasibility and efficacy of this heterogenous suture MSC population in treating craniosynostosis, including Axin2+, Prrx1+, Ctsk+ and CD51+;CD200+ cells. This evidence concerns the gene AXIN2 and craniosynostosis.